Maraviroc as GVHD Prophylaxis in Transplant Recipients
Status:
Terminated
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
The purpose is to determine if the addition of Maraviroc to a standard transplant regimen
will reduce the incidence of graft versus host disease in children and young adults after a
stem cell transplant.